Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02878330




Registration number
NCT02878330
Ethics application status
Date submitted
22/08/2016
Date registered
25/08/2016
Date last updated
14/10/2019

Titles & IDs
Public title
A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants.
Scientific title
A Phase 2b Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants
Secondary ID [1] 0 0
D5290C00003
Universal Trial Number (UTN)
Trial acronym
MEDI8897 Ph2b
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Respiratory Syncytial Virus Infections 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Infection 0 0 0 0
Other infectious diseases
Infection 0 0 0 0
Studies of infection and infectious agents

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - MEDI8897
Treatment: Drugs - Placebo

Placebo comparator: Placebo - Participants will receive a single intramuscular (IM) dose of placebo matched to MEDI8897 on Day 1 of the study.

Experimental: MEDI8897 50 mg - Participants will receive a single IM dose of MEDI8897 50 milligrams (mg) on Day 1 of the study.


Treatment: Drugs: MEDI8897
A single IM dose of 50 mg on Day 1 of the study.

Treatment: Drugs: Placebo
A single IM dose of placebo matched to MEDI8897 on Day 1 of the study.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants With Medically Attended Respiratory Syncytial Virus (RSV) Confirmed Lower Respiratory Tract Infection (LRTI)
Timepoint [1] 0 0
From Day 1 through Day 151
Secondary outcome [1] 0 0
Number of Participants Hopitalized Due to Respiratory Syncytial Virus (RSV) Confirmed Lower Respiartory Tract Infection (LRTI)
Timepoint [1] 0 0
From Day 1 through Day 151
Secondary outcome [2] 0 0
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
Timepoint [2] 0 0
From Day 1 through Day 361
Secondary outcome [3] 0 0
Number of Participants With Adverse Events of Special Interest (AESIs) and New Onset Chronic Diseases (NOCDs)
Timepoint [3] 0 0
From Day 1 through Day 361
Secondary outcome [4] 0 0
Serum Concentration of MEDI8897
Timepoint [4] 0 0
Days 91, 151, and 361
Secondary outcome [5] 0 0
Elimination Half-life (t1/2) of MEDI8897
Timepoint [5] 0 0
Day 91 through Day 361
Secondary outcome [6] 0 0
Number of Participants With Positive Anti-drug Antibodies to MEDI8897
Timepoint [6] 0 0
Days 91, 151, and 361

Eligibility
Key inclusion criteria
Key

1. Healthy infants born between 29 weeks 0 days and 34 weeks 6 days GA.
2. Infants who are entering their first full RSV season at the time of screening.

Key
Minimum age
No limit
Maximum age
365 Days
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
1. Meets American Academy of Pediatrics (AAP) or other local criteria to receive commercial palivizumab.
2. Any fever (>= 100.4°F [>= 38.0°C], regardless of route) or lower respiratory illness within 7 days prior to randomization.
3. Acute illness (defined as the presence of moderate or severe signs and symptoms) at the time of randomization.
4. Active RSV infection (a child with signs/symptoms of respiratory infection must have negative RSV testing) or known prior history of RSV infection.
5. Receipt of palivizumab or other RSV monoclonal antibody or any RSV vaccine, including maternal RSV vaccination.

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
3/11/2016
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
6/12/2018
Sample size
Target
Accrual to date
Final
1453
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Research Site - Parkville
Recruitment hospital [2] 0 0
Research Site - Subiaco
Recruitment postcode(s) [1] 0 0
3052 - Parkville
Recruitment postcode(s) [2] 0 0
6008 - Subiaco
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Massachusetts
Country [10] 0 0
United States of America
State/province [10] 0 0
Michigan
Country [11] 0 0
United States of America
State/province [11] 0 0
Mississippi
Country [12] 0 0
United States of America
State/province [12] 0 0
Missouri
Country [13] 0 0
United States of America
State/province [13] 0 0
Nebraska
Country [14] 0 0
United States of America
State/province [14] 0 0
New York
Country [15] 0 0
United States of America
State/province [15] 0 0
North Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Ohio
Country [17] 0 0
United States of America
State/province [17] 0 0
Oklahoma
Country [18] 0 0
United States of America
State/province [18] 0 0
Oregon
Country [19] 0 0
United States of America
State/province [19] 0 0
Pennsylvania
Country [20] 0 0
United States of America
State/province [20] 0 0
South Carolina
Country [21] 0 0
United States of America
State/province [21] 0 0
South Dakota
Country [22] 0 0
United States of America
State/province [22] 0 0
Tennessee
Country [23] 0 0
United States of America
State/province [23] 0 0
Texas
Country [24] 0 0
United States of America
State/province [24] 0 0
Utah
Country [25] 0 0
United States of America
State/province [25] 0 0
Washington
Country [26] 0 0
United States of America
State/province [26] 0 0
West Virginia
Country [27] 0 0
United States of America
State/province [27] 0 0
Wisconsin
Country [28] 0 0
Argentina
State/province [28] 0 0
Bahía Blanca
Country [29] 0 0
Argentina
State/province [29] 0 0
Guaymallen Mendoza
Country [30] 0 0
Belgium
State/province [30] 0 0
Gent
Country [31] 0 0
Belgium
State/province [31] 0 0
Mons
Country [32] 0 0
Brazil
State/province [32] 0 0
Botucatu
Country [33] 0 0
Brazil
State/province [33] 0 0
Campinas
Country [34] 0 0
Brazil
State/province [34] 0 0
Canoas
Country [35] 0 0
Brazil
State/province [35] 0 0
Curitiba
Country [36] 0 0
Brazil
State/province [36] 0 0
Juiz de Fora
Country [37] 0 0
Brazil
State/province [37] 0 0
Passo Fundo
Country [38] 0 0
Bulgaria
State/province [38] 0 0
Pleven
Country [39] 0 0
Bulgaria
State/province [39] 0 0
Plovdiv
Country [40] 0 0
Bulgaria
State/province [40] 0 0
Ruse
Country [41] 0 0
Bulgaria
State/province [41] 0 0
Sofia
Country [42] 0 0
Canada
State/province [42] 0 0
Quebec
Country [43] 0 0
Chile
State/province [43] 0 0
Maipu
Country [44] 0 0
Chile
State/province [44] 0 0
Santiago
Country [45] 0 0
Chile
State/province [45] 0 0
Valdivia
Country [46] 0 0
Chile
State/province [46] 0 0
Viña del Mar
Country [47] 0 0
Czechia
State/province [47] 0 0
Havlickuv Brod
Country [48] 0 0
Czechia
State/province [48] 0 0
Praha 4
Country [49] 0 0
Estonia
State/province [49] 0 0
Tallinn
Country [50] 0 0
Estonia
State/province [50] 0 0
Tartu
Country [51] 0 0
Finland
State/province [51] 0 0
Tampere
Country [52] 0 0
Finland
State/province [52] 0 0
Turku
Country [53] 0 0
France
State/province [53] 0 0
Bordeaux
Country [54] 0 0
France
State/province [54] 0 0
Brest
Country [55] 0 0
France
State/province [55] 0 0
Bron
Country [56] 0 0
France
State/province [56] 0 0
Caen Cedex
Country [57] 0 0
France
State/province [57] 0 0
Dijon
Country [58] 0 0
France
State/province [58] 0 0
Tours CEDEX 9
Country [59] 0 0
Hungary
State/province [59] 0 0
Budapest
Country [60] 0 0
Hungary
State/province [60] 0 0
Gyula
Country [61] 0 0
Hungary
State/province [61] 0 0
Kecskemét
Country [62] 0 0
Hungary
State/province [62] 0 0
Miskolc
Country [63] 0 0
Hungary
State/province [63] 0 0
Nagykanizsa
Country [64] 0 0
Hungary
State/province [64] 0 0
Nyireyghaza
Country [65] 0 0
Hungary
State/province [65] 0 0
Sopron
Country [66] 0 0
Hungary
State/province [66] 0 0
Szeged
Country [67] 0 0
Hungary
State/province [67] 0 0
Szekszárd
Country [68] 0 0
Hungary
State/province [68] 0 0
Veszprém
Country [69] 0 0
Italy
State/province [69] 0 0
Genova
Country [70] 0 0
Italy
State/province [70] 0 0
Padova
Country [71] 0 0
Italy
State/province [71] 0 0
Torino
Country [72] 0 0
Italy
State/province [72] 0 0
Verona
Country [73] 0 0
Latvia
State/province [73] 0 0
Jekabpils
Country [74] 0 0
Latvia
State/province [74] 0 0
Riga
Country [75] 0 0
Latvia
State/province [75] 0 0
Valmiera
Country [76] 0 0
Lithuania
State/province [76] 0 0
Kaunas
Country [77] 0 0
New Zealand
State/province [77] 0 0
Christchurch
Country [78] 0 0
New Zealand
State/province [78] 0 0
Otahuhu
Country [79] 0 0
New Zealand
State/province [79] 0 0
Wellington
Country [80] 0 0
Poland
State/province [80] 0 0
Bydgoszcz
Country [81] 0 0
Poland
State/province [81] 0 0
Gdansk
Country [82] 0 0
Poland
State/province [82] 0 0
Krakow
Country [83] 0 0
Poland
State/province [83] 0 0
Leczna
Country [84] 0 0
South Africa
State/province [84] 0 0
Cape Town
Country [85] 0 0
South Africa
State/province [85] 0 0
Claremont
Country [86] 0 0
South Africa
State/province [86] 0 0
Durban
Country [87] 0 0
South Africa
State/province [87] 0 0
Johannesburg
Country [88] 0 0
South Africa
State/province [88] 0 0
Pietermaritzburg
Country [89] 0 0
South Africa
State/province [89] 0 0
Pretoria
Country [90] 0 0
Spain
State/province [90] 0 0
Alicante
Country [91] 0 0
Spain
State/province [91] 0 0
Boadilla del Monte
Country [92] 0 0
Spain
State/province [92] 0 0
Cordoba
Country [93] 0 0
Spain
State/province [93] 0 0
Granada
Country [94] 0 0
Spain
State/province [94] 0 0
Lleida
Country [95] 0 0
Spain
State/province [95] 0 0
Madrid
Country [96] 0 0
Spain
State/province [96] 0 0
Málaga
Country [97] 0 0
Spain
State/province [97] 0 0
San Juan de Alicante
Country [98] 0 0
Spain
State/province [98] 0 0
Sant Cugat del Valles
Country [99] 0 0
Spain
State/province [99] 0 0
Santiago de Compostela
Country [100] 0 0
Spain
State/province [100] 0 0
Valencia
Country [101] 0 0
Sweden
State/province [101] 0 0
Stockholm
Country [102] 0 0
Turkey
State/province [102] 0 0
Adana
Country [103] 0 0
Turkey
State/province [103] 0 0
Ankara
Country [104] 0 0
Turkey
State/province [104] 0 0
Antalya
Country [105] 0 0
Turkey
State/province [105] 0 0
Izmir
Country [106] 0 0
Turkey
State/province [106] 0 0
Kocaeli
Country [107] 0 0
United Kingdom
State/province [107] 0 0
Brighton
Country [108] 0 0
United Kingdom
State/province [108] 0 0
Bristol
Country [109] 0 0
United Kingdom
State/province [109] 0 0
London
Country [110] 0 0
United Kingdom
State/province [110] 0 0
Oxford
Country [111] 0 0
United Kingdom
State/province [111] 0 0
Southampton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
MedImmune LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and antidrug antibody (ADA) response for MEDI8897 in healthy preterm infants who are between 29 and 35 weeks gestational age (GA) and entering their first Respiratory Syncytial Virus (RSV) season.
Trial website
https://clinicaltrials.gov/study/NCT02878330
Trial related presentations / publications
Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, Simoes EAF, Esser MT, Khan AA, Dubovsky F, Villafana T, DeVincenzo JP; Nirsevimab Study Group. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. N Engl J Med. 2020 Jul 30;383(5):415-425. doi: 10.1056/NEJMoa1913556. Erratum In: N Engl J Med. 2020 Aug 13;383(7):698. doi: 10.1056/NEJMx200019.
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02878330